Target intelligence / Profile preview

Non-structural protein 5A, hepatitis C virus (NS5A)

Target
NS5A
Molecular classification
Other (Viral protein; nonstructural protein), RNA-binding protein
01

Overview

Non-structural protein 5A of hepatitis C virus (NS5A) is a zinc-binding, proline-rich, hydrophilic phosphoprotein essential for the HCV life cycle[1]. NS5A is processed from a large viral polyprotein and localizes to intracellular membranes via a conserved amphipathic α-helix[3]. It is a key component of the viral replication complex, involved in RNA replication, assembly of infectious viral particles, and interaction with both viral and host proteins[1][2][4]. NS5A coordinates multiple functions through its three domains, particularly domain III, which is critical for particle assembly at lipid droplets via interactions with the viral core protein[2][4]. NS5A also modulates host cell interferon responses, contributing to viral persistence and pathogenesis[1][4]. The protein is the target of several direct-acting antivirals (DAAs), which inhibit its function and disrupt HCV replication, making it a validated therapeutic target in hepatitis C infection. Drug resistance and variability between viral genotypes remain key therapeutic challenges[1].

Other names
NS5AHepatitis C virus NS5AHCV nonstructural protein 5A
02

Mechanism of action

Inhibition of NS5A function, which blocks viral RNA replication and the assembly of new infectious virus particles; Disruption of NS5A-core interactions crucial for particle formation

03

Biological functions

Viral RNA replicationAssembly of infectious viral particlesRegulation of host cell processes and interferon responseMembrane association and replication complex formationModulation of RNA-dependent RNA polymerase activityPotential transcriptional activation
04

Disease associations

Infection (specifically hepatitis C virus infection)Chronic liver disease (including cirrhosis and hepatocellular carcinoma associated with HCV)
05

Safety considerations

Emergent resistance mutations in NS5A can reduce drug efficacyCross-genotype variability in NS5A may affect drug susceptibility and require genotyping before treatmentPotential off-target effects on host cell functions (as NS5A interacts with many cellular pathways)
06

Interacting drugs

Daclatasvir

4 more in the full profile.

07

Biomarkers

NS5A resistance-associated variants/mutations (used for patient selection and efficacy monitoring of NS5A inhibitors)NS5A phosphorylation status in infected cells (explored experimentally)

Beyond the preview

Go deeper on Non-structural protein 5A, hepatitis C virus (NS5A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Non-structural protein 5A, hepatitis C virus (NS5A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call